NYSE:PBH

Stock Analysis Report

Executive Summary

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally.

Snowflake

Fundamentals

Moderate growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Prestige Consumer Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.4%

PBH

1.3%

US Pharmaceuticals

-0.6%

US Market


1 Year Return

-13.7%

PBH

-8.2%

US Pharmaceuticals

0.7%

US Market

PBH underperformed the Pharmaceuticals industry which returned -8.4% over the past year.

PBH underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

PBHIndustryMarket
7 Day-6.4%1.3%-0.6%
30 Day6.0%3.9%4.9%
90 Day9.5%-5.1%1.7%
1 Year-13.7%-13.7%-5.9%-8.2%3.0%0.7%
3 Year-30.8%-30.8%12.9%5.0%44.8%35.4%
5 Year0.3%0.3%22.9%9.8%62.0%44.3%

Price Volatility Vs. Market

How volatile is Prestige Consumer Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

Some Prestige Consumer Healthcare (NYSE:PBH) Shareholders Are Down 34%

Valuation

Is Prestige Consumer Healthcare undervalued based on future cash flows and its price relative to the stock market?

37%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Prestige Consumer Healthcare's share price is below the future cash flow value, and at a moderate discount (> 20%).

Prestige Consumer Healthcare's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Prestige Consumer Healthcare is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Prestige Consumer Healthcare is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Prestige Consumer Healthcare, we can't assess if its growth is good value.


Price Based on Value of Assets

Prestige Consumer Healthcare is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Prestige Consumer Healthcare expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

59.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Prestige Consumer Healthcare's revenue is expected to grow by 0.8% yearly, however this is not considered high growth (20% yearly).

Prestige Consumer Healthcare's earnings are expected to grow significantly at over 20% yearly.

Prestige Consumer Healthcare's revenue growth is positive but not above the United States of America market average.

Prestige Consumer Healthcare's earnings growth is expected to exceed the United States of America market average.

Prestige Consumer Healthcare's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Prestige Consumer Healthcare will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Prestige Consumer Healthcare performed over the past 5 years?

15.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Prestige Consumer Healthcare does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Prestige Consumer Healthcare's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Prestige Consumer Healthcare's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Prestige Consumer Healthcare has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

Prestige Consumer Healthcare used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Prestige Consumer Healthcare improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Prestige Consumer Healthcare's financial position?


Financial Position Analysis

Prestige Consumer Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Prestige Consumer Healthcare's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Prestige Consumer Healthcare's level of debt (161.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (166.8% vs 161.5% today).

Debt is not well covered by operating cash flow (10.5%, less than 20% of total debt).

Prestige Consumer Healthcare is making a loss, therefore interest payments are not well covered by earnings.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.2x debt.


Next Steps

Dividend

What is Prestige Consumer Healthcare's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Prestige Consumer Healthcare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Prestige Consumer Healthcare's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Prestige Consumer Healthcare has not reported any payouts.

Unable to verify if Prestige Consumer Healthcare's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Prestige Consumer Healthcare has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Prestige Consumer Healthcare's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Ron Lombardi (55yo)

4.3yrs

Tenure

US$4,274,547

Compensation

Mr. Ronald M. Lombardi, also known as Ron, has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) since June 2015 and has been its Chai ...


CEO Compensation Analysis

Ron's remuneration is about average for companies of similar size in United States of America.

Ron's compensation has increased whilst company is loss making.


Management Age and Tenure

2.8yrs

Average Tenure

54.5yo

Average Age

The tenure for the Prestige Consumer Healthcare management team is about average.


Board Age and Tenure

4.1yrs

Average Tenure

67yo

Average Age

The tenure for the Prestige Consumer Healthcare board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,300,50020 Nov 18
Timothy Connors
EntityIndividual
Shares34,000
Max PriceUS$38.25
SellUS$557,70015 Nov 18
Timothy Connors
EntityIndividual
Shares14,300
Max PriceUS$39.00

Ownership Breakdown


Management Team

  • Chris Sacco (43yo)

    Chief Financial Officer

    • Tenure: 3yrs
    • Compensation: US$1.54m
  • Phil Terpolilli

    Director of Investor Relations

    • Tenure: 0yrs
  • Bill P'Pool (54yo)

    Senior VP

    • Tenure: 2.8yrs
    • Compensation: US$1.05m
  • Dean Siegal

    Director of Communications

    • Tenure: 0yrs
  • Ron Lombardi (55yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$4.27m
  • Jeff Zerillo (58yo)

    Senior Vice President of Operations

    • Tenure: 1.4yrs
    • Compensation: US$1.01m
  • Mary Fritz

    Senior Vice President of Quality & Regulatory Affairs

    • Tenure: 1.3yrs

Board Members

  • Gary Costley (75yo)

    Lead Independent Director

    • Tenure: 10yrs
    • Compensation: US$235.02k
  • John Byom (65yo)

    Director

    • Tenure: 13.7yrs
    • Compensation: US$227.52k
  • Jim Jenness (73yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$225.02k
  • Nat Ricciardi (70yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$210.02k
  • Chris Coughlin (67yo)

    Director

    • Tenure: 0.2yrs
  • Sheila Hopkins (63yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$210.02k
  • Ron Lombardi (55yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$4.27m

Company Information

Prestige Consumer Healthcare Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Prestige Consumer Healthcare Inc.
  • Ticker: PBH
  • Exchange: NYSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.693b
  • Shares outstanding: 50.24m
  • Website: https://www.prestigebrands.com

Number of Employees


Location

  • Prestige Consumer Healthcare Inc.
  • 660 White Plains Road
  • Suite 250
  • Tarrytown
  • New York
  • 10591
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PBVDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2005
PBHNYSE (New York Stock Exchange)YesCommon StockUSUSDFeb 2005

Biography

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and intern ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:48
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.